These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
137 related items for PubMed ID: 9215398
1. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H. Prostate; 1997 Jul 01; 32(2):106-14. PubMed ID: 9215398 [Abstract] [Full Text] [Related]
2. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959 [Abstract] [Full Text] [Related]
3. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z. Clin Cancer Res; 2002 Jul 15; 8(7):2356-61. PubMed ID: 12114440 [Abstract] [Full Text] [Related]
4. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. Berrevoets CA, Veldscholte J, Mulder E. J Steroid Biochem Mol Biol; 1993 Dec 15; 46(6):731-6. PubMed ID: 8274406 [Abstract] [Full Text] [Related]
6. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Br J Cancer; 1999 Sep 15; 81(2):242-51. PubMed ID: 10496349 [Abstract] [Full Text] [Related]
7. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Prostate; 2005 Dec 01; 65(4):287-98. PubMed ID: 16015608 [Abstract] [Full Text] [Related]
8. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. J Biol Chem; 2003 Jun 06; 278(23):21136-45. PubMed ID: 12665522 [Abstract] [Full Text] [Related]
9. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Wang LG, Liu XM, Kreis W, Budman DR. Biochem Pharmacol; 1998 May 01; 55(9):1427-33. PubMed ID: 10076535 [Abstract] [Full Text] [Related]
10. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Desiniotis A, Schäfer G, Klocker H, Eder IE. Int J Cancer; 2010 Feb 01; 126(3):775-89. PubMed ID: 19653278 [Abstract] [Full Text] [Related]
11. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. Heer R, Robson CN, Shenton BK, Leung HY. J Cell Physiol; 2007 Sep 01; 212(3):572-8. PubMed ID: 17541959 [Abstract] [Full Text] [Related]
12. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Jänne OA. Endocrinology; 1994 Oct 01; 135(4):1359-66. PubMed ID: 7925097 [Abstract] [Full Text] [Related]
13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC, Bevan CL. Clin Cancer Res; 2004 Nov 01; 10(21):7392-401. PubMed ID: 15534116 [Abstract] [Full Text] [Related]
14. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhí JA, Baniahmad A. Mol Endocrinol; 2002 Apr 01; 16(4):661-73. PubMed ID: 11923464 [Abstract] [Full Text] [Related]
15. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276 [Abstract] [Full Text] [Related]
16. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG, Liu XM, Kreis W, Budman DR. Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909 [Abstract] [Full Text] [Related]
17. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer. Shain SA. Mol Urol; 2001 May 27; 5(3):121-30. PubMed ID: 11690559 [Abstract] [Full Text] [Related]
18. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Furr BJ, Tucker H. Urology; 1996 Jan 27; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673 [Abstract] [Full Text] [Related]
19. Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Blok LJ, Themmen AP, Peters AH, Trapman J, Baarends WM, Hoogerbrugge JW, Grootegoed JA. Mol Cell Endocrinol; 1992 Oct 27; 88(1-3):153-64. PubMed ID: 1334008 [Abstract] [Full Text] [Related]
20. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Simard J, Singh SM, Labrie F. Urology; 1997 Apr 27; 49(4):580-6; discussion 586-9. PubMed ID: 9111629 [Abstract] [Full Text] [Related] Page: [Next] [New Search]